Coronavirus Notebook: 1.2bn Vaccines Produced Worldwide, ROVI To Double Moderna Capacity, Valneva starts UK Phase II/III trial
The World Health Organization has updated progress with evaluations of two Chinese vaccines and Russia's Sputnik V, the UK has ordered 60 million more Pfizer/BioNTech doses, and the European Medicines Agency is looking at the use of baricitinib in COVID-19 patients requiring oxygen.
You may also be interested in...
New government funding to boost vaccine manufacturing and research into variant vaccines is being made available as part of the UK’s ambitious plans for a partnership to accelerate the availability of vaccines and other products for future pandemics.
Coronavirus Notebook: EMA Probes Janssen Vaccine Blood Clot Reports, UK Advises 12-Week Dosing Gap For Moderna
The AZ vaccine is now under EU scrutiny over capillary leak syndrome, while Valneva has reported positive results with its product. The global COVAX initiative has delivered more than 38 million doses of vaccines to over a hundred countries.
Regulatory flexibilities such as rolling review, conditional marketing authorizations and possibly an EU emergency use authorization will play a key part in the EU’s plans to identify and approve promising new coronavirus treatments.